FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3095713418> ?p ?o ?g. }

• W3095713418 endingPage "115" @default.
• W3095713418 startingPage "105" @default.
• W3095713418 abstract "Morbidity and mortality associated with COVID-19 has increased exponentially, and patients with cardiovascular (CV) disease are at risk for poor outcomes. Several lines of evidence suggest a potential role for CV therapies in COVID-19 treatment. Characteristics of clinical trials of CV therapies related to COVID-19 registered on ClinicalTrials.gov have not been described. ClinicalTrials.gov was queried on August 7, 2020 for COVID-19 related trials. Studies evaluating established CV drugs, other fibrinolytics (defibrotide), and extracorporeal membrane oxygenation were included. Studies evaluating anti-microbial, convalescent plasma, non-colchicine anti-inflammatory, and other therapies were excluded. Trial characteristics were tabulated from study-specific entries. A total of 2,935 studies related to COVID-19 were registered as of August 7, 2020. Of these, 1,645 were interventional studies, and the final analytic cohort consisted of 114 studies evaluating 10 CV therapeutic categories. Antithrombotics (32.5%; n = 37) were most commonly evaluated, followed by pulmonary vasodilators (14.0%; n = 16), renin-angiotensin-aldosterone system-related therapies (12.3%; n = 14), and colchicine (8.8%; n = 10). Trials evaluating multiple CV therapy categories and CV therapies in combination with non-CV therapies encompassed 4.4% (n = 5) and 9.6% (n = 11) of studies, respectively. Most studies were designed for randomized allocation (87.7%; n = 100), enrollment of less than 1000 participants (86.8%; n = 99), single site implementation (55.3%; n = 63), and had a primary outcome of mortality or a composite including mortality (56.1%; n = 64). Most study populations consisted of patients hospitalized with COVID-19 (81.6%; n = 93). At the time of database query, 28.9% (n = 33) of studies were not yet recruiting and the majority were estimated to be completed after December 2020 (67.8%; n = 78). Most lead sponsors were located in North America (43.9%; n = 50) or Europe (36.0%; n = 41). A minority (7%) of clinical trials related to COVID-19 registered on ClinicalTrials.gov plan to evaluate CV therapies. Of CV therapy studies, most were planned to be single center, enroll less than 1000 inpatients, sponsored by European or North American academic institutions, and estimated to complete after December 2020. Collectively, these findings underscore the need for a network of sites with a platform protocol for rapid evaluation of multiple therapies and generalizability to inform clinical care and health policy for COVID-19 moving forward." @default.
• W3095713418 created "2020-11-09" @default.
• W3095713418 creator A5003376818 @default.
• W3095713418 creator A5004215092 @default.
• W3095713418 creator A5006133112 @default.
• W3095713418 creator A5010571732 @default.
• W3095713418 creator A5014777482 @default.
• W3095713418 creator A5018992472 @default.
• W3095713418 creator A5031359351 @default.
• W3095713418 creator A5049851046 @default.
• W3095713418 creator A5056960938 @default.
• W3095713418 creator A5061823235 @default.
• W3095713418 creator A5061881316 @default.
• W3095713418 creator A5064288485 @default.
• W3095713418 creator A5067237537 @default.
• W3095713418 creator A5074426285 @default.
• W3095713418 date "2021-02-01" @default.
• W3095713418 modified "2023-10-18" @default.
• W3095713418 title "Characteristics of clinical trials evaluating cardiovascular therapies for Coronavirus Disease 2019 Registered on ClinicalTrials.gov: a cross sectional analysis" @default.
• W3095713418 cites W1153335416 @default.
• W3095713418 cites W2002251042 @default.
• W3095713418 cites W2056697517 @default.
• W3095713418 cites W2091671824 @default.
• W3095713418 cites W2146962585 @default.
• W3095713418 cites W2468673334 @default.
• W3095713418 cites W2570787279 @default.
• W3095713418 cites W2899736836 @default.
• W3095713418 cites W2986700515 @default.
• W3095713418 cites W2998391591 @default.
• W3095713418 cites W3005345496 @default.
• W3095713418 cites W3005655936 @default.
• W3095713418 cites W3006834170 @default.
• W3095713418 cites W3008461878 @default.
• W3095713418 cites W3008827533 @default.
• W3095713418 cites W3009885589 @default.
• W3095713418 cites W3011563845 @default.
• W3095713418 cites W3011976215 @default.
• W3095713418 cites W3012747666 @default.
• W3095713418 cites W3013231340 @default.
• W3095713418 cites W3013302817 @default.
• W3095713418 cites W3013648910 @default.
• W3095713418 cites W3013655276 @default.
• W3095713418 cites W3016092214 @default.
• W3095713418 cites W3016587927 @default.
• W3095713418 cites W3017125154 @default.
• W3095713418 cites W3017343267 @default.
• W3095713418 cites W3020735691 @default.
• W3095713418 cites W3027630905 @default.
• W3095713418 cites W3030948568 @default.
• W3095713418 cites W3081761942 @default.
• W3095713418 cites W3082240102 @default.
• W3095713418 cites W4210642183 @default.
• W3095713418 doi "https://doi.org/10.1016/j.ahj.2020.10.065" @default.
• W3095713418 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7586939" @default.
• W3095713418 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33121978" @default.
• W3095713418 hasPublicationYear "2021" @default.
• W3095713418 type Work @default.
• W3095713418 sameAs 3095713418 @default.
• W3095713418 citedByCount "15" @default.
• W3095713418 countsByYear W30957134182020 @default.
• W3095713418 countsByYear W30957134182021 @default.
• W3095713418 countsByYear W30957134182022 @default.
• W3095713418 crossrefType "journal-article" @default.
• W3095713418 hasAuthorship W3095713418A5003376818 @default.
• W3095713418 hasAuthorship W3095713418A5004215092 @default.
• W3095713418 hasAuthorship W3095713418A5006133112 @default.
• W3095713418 hasAuthorship W3095713418A5010571732 @default.
• W3095713418 hasAuthorship W3095713418A5014777482 @default.
• W3095713418 hasAuthorship W3095713418A5018992472 @default.
• W3095713418 hasAuthorship W3095713418A5031359351 @default.
• W3095713418 hasAuthorship W3095713418A5049851046 @default.
• W3095713418 hasAuthorship W3095713418A5056960938 @default.
• W3095713418 hasAuthorship W3095713418A5061823235 @default.
• W3095713418 hasAuthorship W3095713418A5061881316 @default.
• W3095713418 hasAuthorship W3095713418A5064288485 @default.
• W3095713418 hasAuthorship W3095713418A5067237537 @default.
• W3095713418 hasAuthorship W3095713418A5074426285 @default.
• W3095713418 hasBestOaLocation W30957134181 @default.
• W3095713418 hasConcept C126322002 @default.
• W3095713418 hasConcept C168563851 @default.
• W3095713418 hasConcept C2779123688 @default.
• W3095713418 hasConcept C2779134260 @default.
• W3095713418 hasConcept C3008058167 @default.
• W3095713418 hasConcept C524204448 @default.
• W3095713418 hasConcept C535046627 @default.
• W3095713418 hasConcept C71924100 @default.
• W3095713418 hasConceptScore W3095713418C126322002 @default.
• W3095713418 hasConceptScore W3095713418C168563851 @default.
• W3095713418 hasConceptScore W3095713418C2779123688 @default.
• W3095713418 hasConceptScore W3095713418C2779134260 @default.
• W3095713418 hasConceptScore W3095713418C3008058167 @default.
• W3095713418 hasConceptScore W3095713418C524204448 @default.
• W3095713418 hasConceptScore W3095713418C535046627 @default.
• W3095713418 hasConceptScore W3095713418C71924100 @default.
• W3095713418 hasFunder F4320306257 @default.
• W3095713418 hasFunder F4320307115 @default.
• W3095713418 hasFunder F4320307765 @default.
• W3095713418 hasFunder F4320307776 @default.

• next